Promotes CRC progression,increases expression of downstream oncogenic target genes, FAK, IGF1R, EGFR, and YY1 that activate PI3K/AKT and MEK/ERK signaling pathways to promote cancer progression and drug resistance. Here, MAP2K7 is linked to colorectal carcinoma.